THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY
IN, OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND, THE RUSSIAN FEDERATION OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY ORDINARY SHARES OF SCANCELL IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, YOU SHOULD READ AND UNDERSTAND THE INFORMATION PROVIDED IN THE "IMPORTANT NOTICES" SECTION AND IN THE APPENDICES.
Scancell Holdings Plc (LSE:AIM SCLP) ("Scancell" or the "Company"), the developer of novel immunotherapies for the treatment of cancer, further to the announcement on 9 March of the successful Firm Placing to raise £3.4 million, will today publish a circular setting out, amongst other things, details of the Open Offer.
The Open Offer is for up to approximately 22.5 million New Ordinary Shares at 17 pence per New Ordinary Share to raise up to £3.8 million, which will provide Qualifying Shareholders with the opportunity
to subscribe for New Ordinary Shares on the basis of:
1 New Ordinary Share for every 10 Existing Ordinary Shares held
The Firm Placing and Open Offer are within the Company’s existing allotment authorities. The Circular to shareholders will be available shortly on the Company's website at www.scancell.co.uk.
For further information please contact:
Scancell Holdings Plc
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO |
+44 (0) 20 3727 1000 |
| |
|
Panmure Gordon (Nominated Adviser and placing agent)
Robert Naylor/Paul Fincham, Corporate Finance
Maisie Atkinson, Sales |
+44 (0) 20 7886 2500 |
| |
|
Lesmoir-Gordon, Boyle & Co. Limited (Sub placing agent)
Angus Grierson |
+44 (0) 20 7518 9892 |
| |
|
FTI Consulting
Mo Noonan
Simon Conway |
+44 (0) 20 3727 1000 |
Panmure Gordon (UK) Limited is acting as Nominated Adviser and placing agent in respect of the Placing. Lesmoir-Gordon, Boyle & Co. Limited is acting as sub placing agent.
Expected Timetable of Principal Events
| Announcement of the Firm Placing and Open Offer |
9 March |
| Record Date for the Open Offer |
9 March |
| Publication of the Open Offer and the Application Form |
11 March |
| Ex-entitlement Date |
11 March |
| Open Offer Entitlements credited to CREST stock accounts of Qualifying CREST Holders |
14 March |
| Recommended last time and date for requesting withdrawal of Open Offer Entitlements from CREST |
4.30 p.m. on 21 March |
| Latest time and date for depositing Open Offer Entitlements into CREST |
3.00 p.m. on 22 March |
Latest time and date for splitting Application Forms
(to satisfy bona fide market claims only) |
3.00 p.m. on 23 March |
| Latest time and date for acceptance of the Open Offer and receipt of completed Application Forms |
11.00 a.m. on 29 March |
| Announcement of result of Open Offer |
31 March |
| Admission and commencement of dealings in the New Ordinary Shares |
8.00 a.m. on 5 April |
| New Ordinary Shares credited to CREST members’ account |
5 April |
| Despatch of definitive share certificates for New Ordinary Shares in certificated form |
19 April |
The above time and/or dates are subject to change and, in the event of such change, the revised times and/or dates will be notified to Shareholders by an announcement through a Regulatory Information Service.
Dealing codes
The ISIN of the Open Offer Entitlement is GB00BDGSNM16
The ISIN of the Excess Application Facility is GB00BDGSNP47
All defined terms used in this announcement are defined, unless otherwise defined here, in the Proposed Placing and Open Offer announcement made on 9 March 2016.